#	Pagina
attuale pagina	/open-h2020/projects/206528/index.html

Opendata, web and dolomites

MIMESIS SIGNED

A novel systems biology approach to develop preclinical assets from innovative drug discovery starting points inspired by viruses

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

MIMESIS project word cloud

Explore the words cloud of the MIMESIS project. It provides you a very rough idea of what is the project "MIMESIS" about.

never demonstrated initiate previously original patent influenza access unexplored tb me patentable scope drugs rsv biology human inspired infectious discover industry union single successfully unmet discovery fundamental ready innovative mimesis pharmaceutical too leads oncology contexts viruses tractable rate largely directed pipeline points restricted enyo attrition last feasibility context starting transferable classes patients revenue innovation hrv faced generation blockbuster translate dilemmas therapeutic benefit virus ed identification assets emphasis 2015 global tripled disease medical preclinical clinical expirations decade drug medicines chemistries deployment zika diseases

Project "MIMESIS" data sheet

The following table provides information about the project.

Coordinator	ENYO PHARMA Organization address address: 321 AVENUE JEAN JAURES BATIMENT DOMILYON city: LYON postcode: 69007 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	France [FR]
Project website	http://www.enyopharma.com/mimesis/about-mimesis/
Total cost	3˙568˙898 €
EC max contribution	2˙498˙229 € (70%)
Programme	1. H2020-EU.2.1.4. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology) 2. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
Code Call	H2020-SMEINST-2-2016-2017
Funding Scheme	SME-2
Starting year	2016
Duration (year-month-day)	from 2016-11-01 to 2018-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	ENYO PHARMA ENYO PHARMA Organization address address: 321 AVENUE JEAN JAURES BATIMENT DOMILYON city: LYON postcode: 69007 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	FR (LYON)	coordinator	2˙498˙229.00

Map

Project objective

Access to new medicines targeting unmet medical need is a challenge for both the Pharmaceutical industry and the member states of the European union. For the last decade the pharmaceutical sector has faced fundamental dilemmas: - The average cost to develop a single drug has tripled in a decade - Patent expirations have reduced revenue from blockbuster drugs - Attrition in the drug development pipeline remains high. - The rate of innovation in pharmaceutical development is low because of a focus on a restricted number of drug target classes and emphasis on developing “me-too” drugs.

In this context, ENYO has developed an innovative systems biology based approach inspired by viruses to identify patentable chemistries directed at new human disease targets. The feasibility of this approach has been successfully demonstrated in 2015 with the identification of 40 largely unexplored novel human targets against influenza virus, which eventually resulted in the generation of leads ready for development as a therapeutic for influenza.

Project MIMESIS aims to scale-up ENYO’s systems biology approach to discover original preclinical assets against human targets not previously considered tractable to drug development in both infectious (Influenza, HRV, RSV, TB and Zika) and non-infectious disease contexts (Oncology). It will scale-up the number of drug discovery targets and the disease scope and initiate the deployment of the approach to the pharmaceutical industry at the global scale.

The MIMESIS approach will develop novel starting points for the development of new drugs in diseases with unmet clinical need. It will contribute to better access to medicines which will translate into higher pharmaceutical benefit to the patients. The approach has never been used before in the pharmaceutical industry and is transferable to any human disease.

Deliverables

List of deliverables.
Creation of the Business Development Team	Other	2019-05-31 10:46:13
Minimum of 2 peer-reviewed publications, 5 publications in trade journals and 3 publications in general journals with broader audience	Websites, patent fillings, videos etc.	2019-05-31 10:46:05
Project Video Produced	Websites, patent fillings, videos etc.	2019-05-31 10:46:08
Communication and dissemination materials (Intermediary)	Websites, patent fillings, videos etc.	2019-05-31 10:46:08
Creation of the Stakeholders Committee	Other	2019-05-31 10:46:09
Project website development and maintenance	Websites, patent fillings, videos etc.	2019-05-31 10:46:14
Minimum of 5 project presentations at conferences and trade fairs	Websites, patent fillings, videos etc.	2019-05-31 10:48:25
Communication and dissemination materials (Final)	Websites, patent fillings, videos etc.	2019-05-31 10:46:16

Take a look to the deliverables list in detail: detailed list of MIMESIS deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MIMESIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MIMESIS" are provided by the European Opendata Portal: CORDIS opendata.